Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
atorvastatin + cholecalciferol
- Development stage
- Unknown
- Lead developer
- Anthus Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ATAST D3 is a fixed-dose combination therapy developed by Anthus Pharmaceuticals, combining the lipid-lowering agent atorvastatin with vitamin D3 (cholecalciferol). Atorvastatin is an HMG-CoA reductase inhibitor that reduces the synthesis of cholesterol in the liver, thereby lowering low-density lipoprotein (LDL) cholesterol and triglyceride levels while increasing high-density lipoprotein (HDL) cholesterol. Vitamin D3 is a fat-soluble vitamin that is metabolized to its active form, which binds to and activates the vitamin D receptor (VDR), promoting calcium absorption and supporting bone health. This combination is primarily indicated for the management of hypercholesterolemia, dyslipidemia, and co-existing vitamin D deficiency, and it may also help mitigate statin-induced myalgia.
- Brand names
- ATAST D3Astin DAtorec D3Atorfit DAtorsave DAtovastrin D3Avas DDaztorLipicure-DModlip DRemetor-DStorvas DTonact D
- Other names
- atorvastatin + vitamin d3atorvastatin and cholecalciferolatorvastatin and vitamin d3atorvastatin/cholecalciferolatorvastatin/vitamin d3
02
Targets
VDR (Vitamin D receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on atorvastatin + cholecalciferol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on atorvastatin + cholecalciferol.